Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 20, 2016

Primary Completion Date

September 6, 2016

Study Completion Date

November 8, 2016

Conditions
Schizophrenia
Interventions
DRUG

ATI-9242

"Formulated ATI-9242 will be administered as an IV bolus injection (2mg/mL of ATI-9242 in 40% solution of propylene glycol).~Two doses will be tested: single IV bolus injection of 0.5mg/kg and single IV bolus injection 1.0 mg/kg. In the event that a third cohort is needed the IV bolus injection would be 2.0 mg/kg"

RADIATION

[18F]Fallypride Imaging

Subjects will be injected with approximately 250 MBq or 6.75 mCi of \[18F\]Fallypride \[5-6 mCi being the typical range of injected dose\].

Trial Locations (1)

46202

Indiana Clinical Research Center, IU Health University Hospital, Indianapolis

Sponsors
All Listed Sponsors
lead

Braeburn Pharmaceuticals

INDUSTRY